Key result
Factor Xa-activated whole blood clotting time (Xa-ACT) was considerably more sensitive to dalteparin than conventional ACT in vivo (81 s/U vs 22 s/U) and in vitro.
Why the study?
Does Xa-ACT improve monitoring of dalteparin anticoagulation compared to conventional ACT in patients undergoing chronic haemodialysis?
Population
n=9 patients undergoing chronic haemodialysis (HD)
Comparison
Factor Xa-activated whole blood clotting time… vs Conventional activated clotting time (ACT)
Follow-up
up to 4 hours of HD
Authors
Loading...
Xa-ACT may enhance dalteparin monitoring in haemodialysis; leaves open whether it should replace conventional ACT in practice.
Observational (n=9)
Does Xa-ACT improve monitoring of dalteparin anticoagulation compared to conventional ACT in patients undergoing chronic haemodialysis?
Absolute Event Rate: 81% vs 22%
Xa-ACT is superior to conventional ACT for bedside monitoring of dalteparin anticoagulation during haemodialysis.
Frank et al. (2004) conducted an observational in chronic haemodialysis (n=9). Factor Xa-activated whole blood clotting time (Xa-ACT) vs. conventional activated clotting time (ACT) was evaluated on Sensitivity to LMWH in vivo (s/U). Factor Xa-activated whole blood clotting time (Xa-ACT) was considerably more sensitive to dalteparin than conventional ACT in vivo (81 s/U vs 22 s/U) and in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: